Samsung Biologics Co.,Ltd. (207940.KS)
KSE · KRW · Healthcare · Biotechnology
₩1,374,000 (-5.37%) as of
Key statistics
- Market cap
- 63.96T
- Forward P/E
- 29.48
- Dividend yield
- 0.00%
- 52-week range
- 1,150,000.00 – 1,987,000.00
- Beta
- 0.19
- Revenue (TTM)
- 5.12T
- Profit margin
- 38.75%
- Analyst target
- ₩1,879,148.1
- Volume
- 98.29k
About Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Incheon, South Korea
- Employees
- 5,326
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.